The F-prostaglandin receptor is a novel marker for tumor endothelial cells in renal cell carcinoma
The F-prostaglandin receptor is a novel marker for tumor endothelial cells in renal cell carcinoma
复制标题
DOI：
10.1111/pin.12031
复制
发表时间：
2013-01-01
影响因子：
2.2
通讯作者：
Hida, Kyoko
中科院分区：
文献类型：
--
作者：
Akiyama, Kosuke;Ohga, Noritaka;Hida, Kyoko
肿瘤血管生成是肿瘤进展和转移所必需的，因此，肿瘤血管是抗肿瘤治疗中潜在的治疗靶点。我们以前报道过，肿瘤内皮细胞（TEC）表现出不同的表型与正常内皮细胞（NECs）相比，和小鼠TEC和NECs的微阵列分析表明，几个基因在TEC上调与NECs相比。在这些基因中，前列腺素F受体（PTGFR）mRNA的表达水平，其编码的前列腺素F受体（FP），在TEC中高于在NEC中。已有报道FP及其配体前列腺素F2a参与肿瘤血管生成。然而，PTGFR在肾细胞癌（RCC）肿瘤血管中的表达尚未见报道。因此，我们从RCC分离人TEC（hTEC）。PTGFR mRNA在hTECs中的表达水平也上调。免疫组化结果显示PTGFR在体内人肿瘤血管中有表达。这些结果表明，PTGFR是一种新的TEC标志物，它可能是一个新的靶点，抗血管生成治疗RCC。
Tumor angiogenesis is necessary for tumor progression and metastasis; therefore, tumor blood vessels are potential therapeutic targets in anticancer therapy. We previously reported that tumor endothelial cells (TECs) exhibit different phenotypes compared with normal endothelial cells (NECs), and microarray analyses of mouse TECs and NECs have shown that several genes are upregulated in TECs compared with NECs. Among these genes, the expression levels of prostaglandin F receptor (PTGFR) mRNA, which encodes the prostaglandin F receptor (FP), were higher in TECs than in NECs. It has been reported that FP and its ligand, prostaglandin F2a, are involved in tumor angiogenesis. However, there have been no reports of the expression of PTGFR in the tumor vessels of renal cell carcinoma (RCC). Thus, we isolated human TECs (hTECs) from RCCs. The expression levels of PTGFR mRNA were also upregulated in hTECs. In addition, immunostaining showed that the PTGFR was expressed in human tumor blood vessels in vivo. These findings suggested that PTGFR is a novel TEC marker and that it may be a novel target for antiangiogenic therapy for RCC.